Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?

Surcel, C.; Kretschmer, Alexander; Mirvald, C.; Sinescu, I.; Heidegger, Isabel; Tsaur, Igor

doi:10.3390/cancers14030766

Cited by 4 publications

(2 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a Dutch multidisciplinary consensus meeting, more than 80% of panelists responded that PSA kinetics were not important for treatment decisions in synchronous OMPC, whereas more than 60% agreed that it was very important in metachronous OMPC [ 11 ]. In addition to PSA, several biomarkers including genetic markers, circulating tumor cells, and immunologic markers have been investigated showing impractical performance for predicting outcomes [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Yoo,

Park,

Rim

et al. 2024

Current Oncology

View full text Add to dashboard Cite

Background: Interest in the oligometastatic prostate cancer (OMPC) is increasing, and various clinical studies have reported the benefits of metastasis-directed radiation therapy (MDRT) in OMPC. However, the recognition regarding the adopted definitions, methodologies of assessment, and therapeutic approaches is diverse among radiation oncologists. This study aims to evaluate the level of agreement for issues in OMPC among radiation oncologists. Methods: We generated 15 key questions (KQs) for OMPC relevant to definition, diagnosis, local therapies, and endpoints. Additionally, three clinical scenarios representing synchronous metastatic prostate cancer (mPC) (case 1), metachronous mPC with visceral metastasis (case 2), and metachronous mPC with castration-resistance and history of polymetastasis (case 3) were developed. The 15 KQs were adapted according to each scenario and transformed into 23 questions with 6–9 per scenario. The survey was distributed to 80 radiation oncologists throughout the Republic of Korea. Answer options with 0.0–29.9%, 30–49.9%, 50–69.9%, 70–79.9%, 80–89.9%, and 90–100% agreements were considered as no, minimal, weak, moderate, strong, and near perfect agreement, respectively. Results: Forty-five candidates voluntarily participated in this study. Among 23 questions, near perfect (n = 4), strong (n = 3), or moderate (n = 2) agreements were shown in nine. For the case recognized as OMPC with agreements of 93% (case 1), near perfect agreements on the application of definitive radiation therapy (RT) for whole metastatic lesions were achieved. While ≥70% agreements regarding optimal dose-fractionation for metastasis-directed RT (MDRT) has not been achieved, stereotactic body RT (SBRT) is favored by clinicians with higher clinical volume. Conclusion: For the case recognized as OMPC, near perfect agreement for the application of definitive RT for whole metastatic lesions was reached. SBRT was more favored as a MDRT by clinicians with a higher clinical volume.

show abstract

Section: Discussionmentioning

confidence: 99%

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Yoo,

Park,

Rim

et al. 2024

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Risk stratification systems have been developed by various cancer and urological organizations such as the National Comprehensive Cancer Network (NCCN, USA), National Institute for Health and Clinical Excellence (NICE, UK), European Society of Medical Oncology (ESMO), American Urological Association (AUA), and the European Association of Urology (EAU), which are risk stratifying patients by grade group and their serum prostate-specific antigen levels (PSA) into low-risk to very high-risk, with staging imaging indicated for patients with an unfavourable-intermediate risk and above [1,4,5].…”

Section: Introductionmentioning

confidence: 99%

Oligometastatic Prostate Cancer—The Middle Child Syndrome

Lim,

Su,

Saiduzzaman

et al. 2023

JCM

View full text Add to dashboard Cite

Oligometastatic prostate cancer is an evolving clinical entity as more data from novel imaging tools such as PSMA PET/CT emerges. Recognition of this disease entity allows for unique interventions which differ from conventional treatment of metastatic prostate cancers such as the initiation of chemotherapy. With metastasis-directed therapy (MDT), there is potential for early eradication of limited disease metastases and a delay in systemic treatment with its associated treatment-related toxicities. This review explores the current evidence and outcomes of different metastasis-directed therapies such as the role of radiotherapy in low volume metastasis and the use of PSMA ligands to facilitate pelvic lymph node dissections. With a deeper understanding of this low metastasis state, it has revolutionized the current viable treatment options, and more studies are ongoing to provide further insights into this unique disease entity.

show abstract

Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives

et al. 2022

View full text Add to dashboard Cite

Molecular Mechanisms Related with Oligometastatic Prostate Cancer—Is It Just a Matter of Numbers?

Cited by 4 publications

References 82 publications

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group

Oligometastatic Prostate Cancer—The Middle Child Syndrome

Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives

Contact Info

Product

Resources

About